Compare CRNC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | TBPH |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.2M | 993.7M |
| IPO Year | N/A | N/A |
| Metric | CRNC | TBPH |
|---|---|---|
| Price | $11.50 | $18.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $11.50 | ★ $27.80 |
| AVG Volume (30 Days) | ★ 2.0M | 516.8K |
| Earning Date | 11-19-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | ★ $251,781,000.00 | $80,327,000.00 |
| Revenue This Year | $27.55 | $70.78 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $31.31 |
| Revenue Growth | N/A | ★ 27.12 |
| 52 Week Low | $5.94 | $7.90 |
| 52 Week High | $27.50 | $20.33 |
| Indicator | CRNC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 54.58 |
| Support Level | $9.56 | $17.25 |
| Resistance Level | $13.17 | $20.32 |
| Average True Range (ATR) | 0.67 | 0.73 |
| MACD | 0.12 | -0.28 |
| Stochastic Oscillator | 47.47 | 30.62 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).